Have a feature idea you'd love to see implemented?
Let us know!
TNGX Tango Therapeutics Inc
Price (delayed)
$6.29
Market cap
$673.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.12
Enterprise value
$660.21M
tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million
Highlights
The revenue rose by 26% YoY and by 14% QoQ
The gross profit rose by 26% year-on-year and by 14% since the previous quarter
Tango Therapeutics's quick ratio has increased by 26% YoY but it has decreased by 9% from the previous quarter
The equity has increased by 16% YoY but it has decreased by 6% QoQ
The company's net income fell by 9% YoY and by 4.3% QoQ
Key stats
What are the main financial stats of TNGX
Market
Valuations
Earnings
Shares outstanding
107.14M
Market cap
$673.94M
Enterprise value
$660.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.71
Price to sales (P/S)
16.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.53
Revenue
$42.51M
EBIT
-$116.32M
EBITDA
-$110.15M
Free cash flow
-$120.82M
Per share
Balance sheet
Liquidity
EPS
-$1.12
Free cash flow per share
-$1.12
Book value per share
$2.32
Revenue per share
$0.39
TBVPS
$3.52
Total assets
$381.45M
Total liabilities
$133.78M
Debt
$37.84M
Equity
$247.67M
Working capital
$284.54M
Debt to equity
0.15
Current ratio
7.49
Quick ratio
7.34
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
-259.1%
Gross margin
100%
Net margin
-274%
Operating margin
-311.6%
Return on assets
-28.8%
Return on equity
-44.7%
Return on invested capital
-34.3%
Return on capital employed
-34.5%
Return on sales
-273.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TNGX stock price
How has the Tango Therapeutics stock price performed over time
Intraday
0.32%
1 week
-10.14%
1 month
-15.57%
1 year
-12.52%
YTD
-36.46%
QTD
-18.31%
Financial performance
How have Tango Therapeutics's revenue and profit performed over time
Revenue
$42.51M
Gross profit
$42.51M
Operating income
-$132.45M
Net income
-$116.49M
Gross margin
100%
Net margin
-274%
The revenue rose by 26% YoY and by 14% QoQ
The gross profit rose by 26% year-on-year and by 14% since the previous quarter
Tango Therapeutics's operating income has decreased by 16% YoY and by 5% QoQ
The net margin has grown by 14% YoY and by 9% from the previous quarter
Growth
What is Tango Therapeutics's growth rate over time
Valuation
What is Tango Therapeutics stock price valuation
P/E
N/A
P/B
2.71
P/S
16.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.53
Tango Therapeutics's EPS has increased by 7% YoY
The stock's P/B is 25% less than its last 4 quarters average of 3.6
The equity has increased by 16% YoY but it has decreased by 6% QoQ
TNGX's price to sales (P/S) is 36% lower than its last 4 quarters average of 24.9
The revenue rose by 26% YoY and by 14% QoQ
Efficiency
How efficient is Tango Therapeutics business performance
Tango Therapeutics's return on sales has increased by 14% YoY and by 9% QoQ
The ROA is down by 13% year-on-year and by 4.3% since the previous quarter
TNGX's ROIC is down by 8% YoY and by 2.4% from the previous quarter
Dividends
What is TNGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TNGX.
Financial health
How did Tango Therapeutics financials performed over time
The total assets is 185% more than the total liabilities
Tango Therapeutics's quick ratio has increased by 26% YoY but it has decreased by 9% from the previous quarter
The current ratio has grown by 25% YoY but it has contracted by 9% from the previous quarter
The debt is 85% less than the equity
The debt to equity has declined by 21% year-on-year but it has grown by 7% since the previous quarter
The equity has increased by 16% YoY but it has decreased by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.